Safety and efficacy of combination therapy using programmed cell death protein‐1/programmed cell death ligand‐1 inhibitors and radiotherapy in patients with non‐small‐cell lung cancer: A systematic review and meta‐analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of combination therapy using programmed cell death protein‐1/programmed cell death ligand‐1 inhibitors and radiotherapy in patients with non‐small‐cell lung cancer: A systematic review and meta‐analysis
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-01-20
DOI
10.1002/cam4.3718
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
- (2020) Tomoya Fukui et al. Thoracic Cancer
- Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer
- (2020) Salma K. Jabbour et al. JAMA Oncology
- Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials.
- (2020) James William Welsh et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A U.S. Food and Drug Administration pooled analysis.
- (2020) Mitchell Steven Anscher et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
- (2020) Yu Miura et al. Thoracic Cancer
- Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
- (2020) Chia‐Hsun Chu et al. Thoracic Cancer
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
- (2019) Ou Yamaguchi et al. Thoracic Cancer
- Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy
- (2019) Mengqian Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non–small cell lung cancer with brain metastases
- (2019) Charu Singh et al. JOURNAL OF NEUROSURGERY
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
- (2019) Yoshiaki Amino et al. International Journal of Clinical Oncology
- Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer
- (2019) Yeona Cho et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- 1459PDEfficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
- (2019) J F Vansteenkiste et al. ANNALS OF ONCOLOGY
- Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
- (2019) Gishan Ratnayake et al. Asia-Pacific Journal of Clinical Oncology
- A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
- (2019) Angel Qin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy
- (2019) Eun-Ah Choe et al. LUNG CANCER
- Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases
- (2018) Emily Schapira et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study
- (2018) Long Ge et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Reporting of declarations and conflicts of interest in WHO guidelines can be further improved
- (2018) Xiaoqin Wang et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer
- (2018) Harper G. Hubbeling et al. Journal of Thoracic Oncology
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
- (2018) Aaron Lisberg et al. Cancer Immunology Research
- Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
- (2018) C. Bryce Johnson et al. OncoImmunology
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
- (2018) William L. Hwang et al. JAMA Oncology
- Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy
- (2018) Taylor R Cushman et al. Immunotherapy
- Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
- (2018) Paul Lesueur et al. Cancer Medicine
- The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study
- (2018) Peijing Yan et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The methodological and reporting quality of systematic reviews from China and the USA are similar
- (2017) Jinhui Tian et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases
- (2017) Kamran A. Ahmed et al. JOURNAL OF NEURO-ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- The quality of evidence in Chinese meta-analyses needs to be improved
- (2016) Liang Yao et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
- (2016) Michael B. Bernstein et al. Nature Reviews Clinical Oncology
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- (2015) Kobe Reynders et al. CANCER TREATMENT REVIEWS
- The reporting characteristics and methodological quality of Cochrane reviews about health policy research
- (2015) Li Xiu-xia et al. HEALTH POLICY
- Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China
- (2015) ShengFa Su et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties
- (2015) Dawid Pieper et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
- (2014) S. Matsumura et al. JOURNAL OF IMMUNOLOGY
- Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
- (2014) Abdul Qader Sukkurwala et al. OncoImmunology
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
- (2013) Felix Klug et al. CANCER CELL
- Immunologically augmented cancer treatment using modern radiotherapy
- (2013) Marco Durante et al. TRENDS IN MOLECULAR MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started